In Situ Hybridization Market Size and Share Analysis by Product, Technology, Application, End User

Description

In 2023, the in-situ hybridization market amounted to USD 1,742.3 million and is set to grow at a compound annual growth rate of 12.8% between 2024 and 2030 reaching an estimated amount of USD 4,017.3 million by 2030.

This development of the market can be credited to the increasing acceptance of the in-situ hybridization (ISH) process for identifying numerous genetic illnesses and cancer, the rising pace of improvements in this method, and growing private and public funding for the research and development sector. Moreover, the rising demand for modified medicines is projected to fuel the industry growth.

There has been a distressing surge in cases of cancer worldwide in the past few years. This has caused a surge in the number of examined studies connected with this illness and those revolving around certain genomic irregularities, which are likely risk factors for numerous types of carcinomas.

IHC and DNA FISH are combined by the cytogenetic ISH technology, therefore completing the in-situ toolkit, which allows scientists to find, create, and utilize next-generation diagnostic methods. With direct imaging, in-situ RNA-level gene expression provides a diverse perspective on the interaction between cancerous cells and the tumor microenvironment as the illness develops. This pattern is also observed in certain genetic syndromes.

In 2023, based on product, the consumables category is dominating the market with revenue of over USD 0.8 billion, and the category is also projected to dominate the market in the future as well. The increasing need for consumables is because of the extensive utilization of kits in studies, because of which they are constantly bought.

An in-situ hybridization kit comes with the hybridization solution, pre-hybridization solution, SSC buffer, BCIP & NBT detection reagents, blocking solution, an anti-Dig antibody, and alkaline phosphatase buffer. Increasing use of these kits for prehybridization and after-hybridization has been a driving force in the category's growth. Such kits permit operators to recognize specific nucleic acids in cells and hence tissues, which are being progressively accepted in research amenities.

In 2023, the FISH technology had a significant share, credited to the extensive variety of applications of this tech in diagnostics, like characterization with the aid of marker chromosomes, finding of numerical and structural chromosome flaws, finding of unusual and hereditary conditions, and drug abuse tracking.

In 2023, the North American region, generated the largest revenue share, of 55%, in the worldwide industry for in-situ hybridization solutions. The North American industry is projected to continue to uphold its dominating position during the projection period, mainly credited to the increasing count of autosomal diseases, cancer cases, genetic disorders, and also communicable conditions in the continent.

The U.S. is the key revenue generator in North America, mainly because of the strong government and private backing for the growth of new companion diagnostics methods.

Product Code: 12731

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by disease type
- 1.4.3. Market size breakdown, by route of administration
- 1.4.4. Market size breakdown, by application
- 1.4.5. Market size breakdown, by region
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Product (2017-2030)
6.3. Market Revenue, by Disease Type (2017-2030)
6.4. Market Revenue, by Route of Administration (2017-2030)
6.5. Market Revenue, by Application (2017-2030)
6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Product (2017-2030)
7.3. Market Revenue, by Disease Type (2017-2030)
7.4. Market Revenue, by Route of Administration (2017-2030)
7.5. Market Revenue, by Application (2017-2030)
7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Product (2017-2030)
8.3. Market Revenue, by Disease Type (2017-2030)
8.4. Market Revenue, by Route of Administration (2017-2030)
8.5. Market Revenue, by Application (2017-2030)
8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Product (2017-2030)
9.3. Market Revenue, by Disease Type (2017-2030)
9.4. Market Revenue, by Route of Administration (2017-2030)
9.5. Market Revenue, by Application (2017-2030)
9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Product (2017-2030)
10.3. Market Revenue, by Disease Type (2017-2030)
10.4. Market Revenue, by Route of Administration (2017-2030)
10.5. Market Revenue, by Application (2017-2030)
10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Product (2017-2030)
11.3. Market Revenue, by Disease Type (2017-2030)
11.4. Market Revenue, by Route of Administration (2017-2030)
11.5. Market Revenue, by Application (2017-2030)
11.6. Market Revenue, by Country (2017-2030)

Chapter 12. Competitive Landscape

12.1. List of Market Players and their Offerings
12.2. Competitive Benchmarking of Key Players
12.3. Product Benchmarking of Key Players
12.4. Recent Strategic Developments

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc.
- 13.1.1. Business overview
- 13.1.2. Product and service offerings
- 13.1.3. Key financial summary
13.2. Dynavax Technologies
- 13.2.1. Business overview
- 13.2.2. Product and service offerings
- 13.2.3. Key financial summary
13.3. Novavax
- 13.3.1. Business overview
- 13.3.2. Product and service offerings
- 13.3.3. Key financial summary
13.4. Agenus Inc.
- 13.4.1. Business overview
- 13.4.2. Product and service offerings
- 13.4.3. Key financial summary
13.5. Croda International plc
- 13.5.1. Business overview
- 13.5.2. Product and service offerings
- 13.5.3. Key financial summary
13.6. Seppic
- 13.6.1. Business overview
- 13.6.2. Product and service offerings
13.7. OZ Biosciences
- 13.7.1. Business overview
- 13.7.2. Product and service offerings
13.8. Merck KGaA
- 13.8.1. Business overview
- 13.8.2. Product and service offerings
- 13.8.3. Key financial summary
13.9. InvivoGen
- 13.9.1. Business overview
- 13.9.2. Product and service offerings
13.10. SPI Pharma
- 13.10.1. Business overview
- 13.10.2. Product and service offerings
13.11. Aurorium Holdings LLC
- 13.11.1. Business overview
- 13.11.2. Product and service offerings
13.12. EuBiologics Co., Ltd
- 13.12.1. Business overview
- 13.12.2. Product and service offerings
- 13.12.3. Key financial summary
13.13. Phibro Animal Health Corporation
- 13.13.1. Business overview
- 13.13.2. Product and service offerings
- 13.13.3. Key financial summary
13.14. Shionogi & Co., Ltd.
- 13.14.1. Business overview
- 13.14.2. Product and service offerings
- 13.14.3. Key financial summary

Chapter 14. Appendix

14.1. Abbreviations
14.2. Sources and References
14.3. Related Reports

In Situ Hybridization Market Size and Share Analysis by Product, Technology, Application, End User - Global Industry Demand Forecast to 2030